Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT).
 Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients
 following transplantation and causes a persistent infection that leads to chronic hepatitis
 and cirrhosis in a significant proportion of patients. To date there is no effective way to
 prevent HCV reinfection of the liver graft in the early phase after transplantation. . Early
 passive immunotherapy with neutralizing antibodies against HCV should be considered for
 preventing reinfection of liver transplanted patients associated with HCV. This approach is
 well established in the case of patients undergoing liver transplantation for chronic
 hepatitis B virus infection. Our purpose is to produce neutralizing monoclonal antibodies to
 prevent reinfection of the liver graft.
Inclusion Criteria:

 -  Health insurance

 -  Resolved HCV infection ( HCV RNA negative since more then 6 months ) -HCV chronically
 infected ( RNA positive )

 -  Anti- HCV antibodies positive

 -  Volunteers and informed patients

 Exclusion Criteria:

 -  Immunosuppression

 -  HBV or HIV infection

 -  Pregnancy

 -  Breast feeding